Main Article Content
Introduction: The major cause of maternal morbidity and mortality globally is "postpartum haemorrhage (PPH)". It has been demonstrated that anti-fibrinolytic medications lower blood loss and PPH incidence. Limited information is available, though, regarding how well these medications control blood loss during caesarean section and vaginal delivery. Therefore, the purpose of this study was to assess the effectiveness of anti-fibrinolytic medications for the treatment of blood loss following caesarean section and vaginal delivery.
Methods: Between January 2021 and June 2022, a case-control research was carried out at a tertiary care hospital in India. The study involved a total of 200 women who gave birth naturally or via caesarean section. Anti-fibrinolytic medications were given to the intervention group, while no interventions were given to the control group. The incidence of PPH served as the primary outcome indicator, whereas the incidence of adverse events and the need for blood transfusions served as supplementary end indicators.
Results: When compared to the control group, the intervention group's incidence of PPH was considerably lower (16% vs. 32%, p=0.02). The number of people who required to be treated to stop one instance of PPH was 6.3, and the overall risk reduction was 16%. Blood transfusion requirements were considerably lower in the intervention group (4% vs. 14%, p=0.03) than in the control group. The frequency of negative outcomes did not significantly differ between the two groups.
Conclusion: After vaginal delivery and caesarean section, anti-fibrinolytic medications effectively reduce blood loss and the occurrence of PPH. Additionally safe, these medications don't raise the chance of negative side effects. Anti-fibrinolytic medications should therefore be viewed as a standard intervention for the management of blood loss during caesarean section and vaginal delivery.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.